ENTPD1 and neoplasm: CD39+ CD8 TRM cells have been well characterized as a highly tumor-reactive subset of CD8 TRM cells in non–small-cell lung cancer [6], head and neck cancer [14], and endometrial cancer [23], but they have never been investigated in HCC.